Pharma BD Deal Intelligence

Piramal Pharma Limited / Yapan Bio Private Limited

2026 · Acquisition/Merger · $8M · Complete

Piramal Pharma Limited completed the acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited, a Hyderabad-based vaccines and biologics contract development and manufacturing organisation, for aggregate cash consideration of Rs 76 crore (approximately USD 7.95 million). Piramal exercised a call option to lift its holding from 33.33% to 74.00%, converting Yapan Bio from an associate company into a subsidiary. Yapan Bio's large-molecule capabilities will be integrated into the Piramal Pharma Solutions service offering to broaden development and manufacturing services for complex biologics.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals